İmmün Trombositopeni

Cheng, C.K.W., Chan, J., Cembrowski, et al. Complete blood count reference interval diagrams derived from NHANES III: stratification by age, sex, and race. Laboratory Hematology, 2004; 42-53.

Barsam, S. J., Psaila, B., Forester M., et.al. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood, The Journal of the American Society of Hematology, 2011; 117(21), 5723-5732.

Wilon DB. Acquired platelet disorders. Nathan and Oski's Hematology and Oncology of Infancy and Childhood. 8th ed. 2015: 1076-1102

Despotovic, J. M. Causes of thrombocytopenia in children, Up to Date, 2022.

Despotovic, J. M. Approach to the child unexplained thrombocytopenia. Up to Date, 2022.

Catherine MG., James B. B. Disorders of platelets. Lanzkowsky's Manual of Pediatric Hematology and Oncology, Seventh ed., 2022: 237-284

Kumar, R., Kahr, W. H. Congenital thrombocytopenia: clinical manifestations, laboratory abnormalities, and molecular defects of a heterogeneous group of conditions. Hematology/Oncology Clinics, 2013. 27(3), 465-494.

Stasi, R. (2012). How to approach thrombocytopenia. Hematology 2010, the American Society of Hematology Education Program Book, 2012(1), 191-197.

Bussel, J. B. Immune thrombocytopenia (ITP) in children: Clinical features and diagnosis. Up to Date, 2022.

Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113:2386.

D’Orazio, J. A., Neely, J., Farhoudi, N. ITP in children: pathophysiology and current treatment approaches. Journal of pediatric hematology/oncology, 2013. 35(1), 1-13.

Bussel, J. B. Immune thrombocytopenia in children: Initial management: Up to Date, 2022.

Provan, D., Stasi, R., Newland, A. C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 2010. 168-186.

Neunert, C., Terrell, D. R., Arnold, D. M., et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood advances 2019, 3(23), 3829-3866.

Kühne, T., Imbach, P., Bolton-Maggs, et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. The lancet, 2001. 358, 2122-2125.

Price V. Auto-immune lymphoproliferative disorder and other secondary immune thrombocytopenias in childhood. Pediatr Blood Cancer 2013. 60 Supp. 1:S12

Chong, Beng H. Diagnosis, treatment and pathophysiology of autoimmune thrombocytopenias. Critical reviews in oncology/hematology 20.3, 1995. 271-296.

Kühne, T., Buchanan, G. R., Zimmerman, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. The Journal of pediatrics, 2003. 143(5), 605-608.

Vesely, S., Buchanan, G. R., Cohen A., et al. Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: results of a survey of practicing pediatric hematology/oncology specialists. J. of ped. hematology/oncology, 2000. 22(1), 55-61.

Rotz, S. J., Ware, R.E, Kumar A. Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults. Pediatric Blood & Cancer, 2018. 65 e27260.

Grace, R. F., Shimano, K. A., Bhat, R., et al. Second‐line treatments in children with immune thrombocytopenia: effect on platelet count and patient‐centered outcomes. American journal of hematology, 2019. 94(7), 741-750.

Bansal D, Bhamare TA, Trehan A, et al. Outcome of chronic idiopathic thrombocytopenic purpura in children. Pediatr Blood Cancer 2010; 54: 403-407

Cheng, C.K.W., Chan, J., Cembrowski, et al. Complete blood count reference interval diagrams derived from NHANES III: stratification by age, sex, and race. Laboratory Hematology, 2004; 42-53.

Barsam, S. J., Psaila, B., Forester M., et.al. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood, The Journal of the American Society of Hematology, 2011; 117(21), 5723-5732.

Wilon DB. Acquired platelet disorders. Nathan and Oski's Hematology and Oncology of Infancy and Childhood. 8th ed. 2015: 1076-1102

Despotovic, J. M. Causes of thrombocytopenia in children, Up to Date, 2022.

Despotovic, J. M. Approach to the child unexplained thrombocytopenia. Up to Date, 2022.

Catherine MG., James B. B. Disorders of platelets. Lanzkowsky's Manual of Pediatric Hematology and Oncology, Seventh ed., 2022: 237-284

Kumar, R., Kahr, W. H. Congenital thrombocytopenia: clinical manifestations, laboratory abnormalities, and molecular defects of a heterogeneous group of conditions. Hematology/Oncology Clinics, 2013. 27(3), 465-494.

Stasi, R. (2012). How to approach thrombocytopenia. Hematology 2010, the American Society of Hematology Education Program Book, 2012(1), 191-197.

Bussel, J. B. Immune thrombocytopenia (ITP) in children: Clinical features and diagnosis. Up to Date, 2022.

Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113:2386.

D’Orazio, J. A., Neely, J., Farhoudi, N. ITP in children: pathophysiology and current treatment approaches. Journal of pediatric hematology/oncology, 2013. 35(1), 1-13.

Bussel, J. B. Immune thrombocytopenia in children: Initial management: Up to Date, 2022.

Provan, D., Stasi, R., Newland, A. C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 2010. 168-186.

Neunert, C., Terrell, D. R., Arnold, D. M., et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood advances 2019, 3(23), 3829-3866.

Kühne, T., Imbach, P., Bolton-Maggs, et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. The lancet, 2001. 358, 2122-2125.

Price V. Auto-immune lymphoproliferative disorder and other secondary immune thrombocytopenias in childhood. Pediatr Blood Cancer 2013. 60 Supp. 1:S12

Chong, Beng H. Diagnosis, treatment and pathophysiology of autoimmune thrombocytopenias. Critical reviews in oncology/hematology 20.3, 1995. 271-296.

Kühne, T., Buchanan, G. R., Zimmerman, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. The Journal of pediatrics, 2003. 143(5), 605-608.

Vesely, S., Buchanan, G. R., Cohen A., et al. Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: results of a survey of practicing pediatric hematology/oncology specialists. J. of ped. hematology/oncology, 2000. 22(1), 55-61.

Rotz, S. J., Ware, R.E, Kumar A. Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults. Pediatric Blood & Cancer, 2018. 65 e27260.

Grace, R. F., Shimano, K. A., Bhat, R., et al. Second‐line treatments in children with immune thrombocytopenia: effect on platelet count and patient‐centered outcomes. American journal of hematology, 2019. 94(7), 741-750.

Bansal D, Bhamare TA, Trehan A, et al. Outcome of chronic idiopathic thrombocytopenic purpura in children. Pediatr Blood Cancer 2010; 54: 403-407